Related Experiment Video

Updated: Aug 21, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

[The place of targeted treatments: receptor tyrosine kinase inhibitors]

J-M Bréchot1

  • 1Service d'Oncologie Médicale, CHU Avicenne, 125, route de Stalingrad, 93009 Bobigny. jeanne-marie.brechot@avc.ap-hop-paris.fr

Revue De Pneumologie Clinique
|November 13, 2004
PubMed

Insights

Targeted biological treatments, including monoclonal antibodies and tyrosine kinase inhibitors, show promise in pulmonary oncology by targeting abnormal cancer cell mechanisms like HER and VEGF receptors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Signal transduction pathways in cancer cells often involve receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGF).
  • Aberrant signaling through these pathways drives tumor growth and progression in various cancers, including lung cancer.

Purpose:

  • To review preliminary studies on targeted biological treatments in pulmonary oncology.
  • To discuss the mechanisms of action for novel cancer therapies targeting specific molecular abnormalities.

Summary:

  • Targeted therapies aim to correct specific cancer cell abnormalities by interfering with key signaling pathways.
  • Examples include monoclonal antibodies (e.g., bevacizumab targeting VEGF, cetuximab targeting EGFR) and tyrosine kinase inhibitors (e.g., gefitinib, erlotinib targeting intracellular receptor segments).
  • These agents block either the ligand or the receptor itself, disrupting downstream signaling.

Impact:

  • Preliminary findings suggest these targeted treatments offer new therapeutic strategies for lung cancer.
  • Understanding these targeted approaches is crucial for advancing personalized medicine in oncology.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.